ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference
21 nov. 2022 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference
08 nov. 2022 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
28 oct. 2022 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022; expected runway through late 2023New TREK-DX clinical...
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting
28 sept. 2022 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
First data from collaboration with Dr Shawn Kwatra and Dr Madan Kwatra show increased IL-13Rα1 expression on mast cells and eosinophils in skin samples from atopic dermatitis (AD) patients,...
ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
14 sept. 2022 07h15 HE
|
ASLAN PHARMACEUTICALS LIMITED
ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to evaluate the efficacy and safety of eblasakimab as an alternative biologic in...
ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting
13 sept. 2022 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Sept. 13, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress
07 sept. 2022 06h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
Data presented at EADV for the first time show eblasakimab suppresses downstream inflammatory biomarkers of atopic dermatitis, continuing 4-6 weeks after the last dose Notable improvements in...
ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
02 sept. 2022 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Signs License Agreement With Belle.ai to Use belleStudy™ Image Capture Software in Atopic Dermatitis Clinical Trials
25 août 2022 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and CAMBRIDGE, Mass. and SINGAPORE, Aug. 25, 2022 (GLOBE NEWSWIRE) -- BelleTorus Corporation (“Belle.ai”) and ASLAN Pharmaceuticals (Nasdaq: ASLN), today announced that ASLAN has...
ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022
22 août 2022 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
Management team will host R&D day on Thursday, September 15, from 10am ET in New York City with Key Opinion Leader (KOL) participationPipeline and business update, translational and clinical data...